Published January 1, 2021 | Version v1
Journal article Open

Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids

  • 1. Ege Univ, Dept Pharmaceut Biotechnol, Izmir, Turkey
  • 2. Izmir Univ Econ, Fac Engn, Dept Genet & Bioengn, Izmir, Turkey

Description

Background: siRNAs hold a great potential for cancer therapy, however, poor stability in body fluids and low cellular uptake limit their use in the clinic. To enhance the bioavailability of siRNAs in tumors, novel, safe, and effective carriers are needed.

Files

bib-5198cc96-6754-4505-a3f8-3a1adb0cb997.txt

Files (315 Bytes)

Name Size Download all
md5:9c56b9e30d4661313285b39c1951e0dc
315 Bytes Preview Download